GMO Trust has filed a new prospectus for its GMO Benchmark-Free Allocation Fund, which outlines the fund's fees, investment strategies, and objectives. This filing is significant as it reflects the company's ongoing commitment to providing clear and comprehensive information to investors.
GMO Trust, based in Boston, Massachusetts, is an investment entity that specializes in various mutual funds. The company has a history of focusing on innovative investment strategies and transparency in its operations. The recent filing is part of a series of updates, with multiple filings made on October 20, 2026, including the 497K form with accession number 0001193125-26-426637.
What the Filing Says
The new prospectus highlights the management fees for the fund, which are set at 0.80% for both Class R6 and Class I shares. Other expenses include a minimal additional cost, making the total annual fund operating expenses approximately 1.50% for Class R6 and 1.61% for Class I. The filing emphasizes that the fund aims for positive total returns and outlines its investment objective of achieving annualized returns of 5% above the Consumer Price Index.
Impact
This update may affect existing and potential investors in the GMO Benchmark-Free Allocation Fund by providing them with clearer insights into the costs associated with their investments. Additionally, the detailed disclosure may prompt other firms in the investment industry to enhance their own prospectus offerings to ensure they remain competitive.
What's Next
The filing does not specify what happens next regarding further updates or changes to the fund's structure.